<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419327</url>
  </required_header>
  <id_info>
    <org_study_id>15077</org_study_id>
    <nct_id>NCT01419327</nct_id>
  </id_info>
  <brief_title>Fosrenol Post-marketing Surveillance for Hemodialysis in Japan</brief_title>
  <acronym>FOSRENOL-HD</acronym>
  <official_title>Special Drug Use Investigation of Fosrenol (Long-term Investigation for Patients With Hemodialysis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a regulatory post marketing surveillance in Japan, and it is a local
      prospective and observational study of patients in hemodialysis who received Fosrenol for
      hyperphosphatemia. The objective of this study is to assess safety and efficacy of using
      Fosrenol in clinical practice. A total 3,000 patients will be recruited and followed 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 23, 2009</start_date>
  <completion_date type="Actual">May 28, 2019</completion_date>
  <primary_completion_date type="Actual">January 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse drug reactions in subjects who received Fosrenol</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timing of onset of common ADRs related to the priority survey items</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
    <description>The items are
Gastrointestinal symptoms
Secondary hyperparathyroidism
Hypocalcaemia and decreased blood calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on bones: Alkaline phosphatase over time</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on bones: Change in bone density</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiothoracic ratio over time</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PWV and ABI over time</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum P, albumin-corrected serum Ca and serum intact PTH, and Ca-P product over time</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving the serum P control goal</measure>
    <time_frame>After Fosrenol administration, up to 8 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3267</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Drug (incl. Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet</intervention_name>
    <description>Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The target population of this study is patients who have received a prescription of
        Fosrenol on the basis of the decision of the physician. The study is expected to collect
        data of 3,000 patients in about 300 practices in Japan.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing hemodialysis who received Fosrenol for hyperphosphatemia

        Exclusion Criteria:

          -  Patients who are contraindicated based on the product label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer products</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fosrenol</keyword>
  <keyword>Hyperphosphatemia</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

